Adagene (ADAG) Share-based Compensation (2020 - 2026)
Adagene (ADAG) posted quarterly Share-based Compensation of $5.2 million for Q4 2025, down 10.27% year-over-year from $5.8 million in Q4 2024, and down 36.47% quarter-over-quarter from $8.2 million in Q2 2025.
Analysis
Adagene (ADAG) Share-based Compensation (2020 - 2026) Analysis & Trends
Adagene (ADAG) has reported Share-based Compensation for 6 consecutive years, with $5.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Share-based Compensation fell 10.27% year-over-year to $5.2 million; the TTM figure through Dec 2025 stood at $5.2 million (down 10.27% YoY), while the FY2025 annual figure was $5.2 million, down 10.27% from the prior year.
- Share-based Compensation fell to $5.2 million in Q4 2025 per ADAG's latest filing, from $8.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $30.6 million in Q4 2021 and bottomed at $5.2 million in Q4 2025.
- Historically, Share-based Compensation has averaged $14.9 million across 5 years, with a median of $14.1 million in 2024.
- Annual changes were most pronounced in 2021 — Share-based Compensation retreated 10.23% — and 2024, when it tumbled 65.32%.
- Adagene's Share-based Compensation stood at $30.6 million in 2021, then fell by 22.78% to $23.6 million in 2022, then dropped by 29.52% to $16.7 million in 2023, then sank by 65.32% to $5.8 million in 2024, then slipped by 10.27% to $5.2 million in 2025.
- Business Quant data shows ADAG's Share-based Compensation at $5.2 million in Q4 2025, $8.2 million in Q2 2025, and $5.8 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 120.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 277.20 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 137.41 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 86.63 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Adagene | 211.24 Mn | 211.24 Mn | - | 6.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.86 Mn |
| Dec 31, 2025 | 5.18 Mn |
| Jun 30, 2025 | 8.16 Mn |
| Dec 31, 2024 | 5.78 Mn |
| Jun 30, 2024 | 14.11 Mn |
| Dec 31, 2023 | 16.66 Mn |
| Jun 30, 2023 | 7.62 Mn |
| Dec 31, 2022 | 23.64 Mn |
| Dec 31, 2021 | 30.61 Mn |
| Dec 31, 2020 | 34.10 Mn |